AI Revolutionizes Indian Pharma: From Experimentation to Delivery by 2026

• Artificial intelligence is rapidly transforming global pharma and healthcare, with major partnerships like NVIDIA-Eli Lilly AI co-innovation lab highlighting its importance.
• India's pharma sector is moving from AI awareness to early adoption, with about 20% of companies already deploying AI for documentation, quality analytics, and operational workflows.
• BCG predicts 2026 will be a pivotal year for AI in Indian pharma, shifting from experimentation to widespread delivery and scale.
• AI is expected to significantly impact small-molecule drug discovery in the next 1-2 years, accelerating molecule optimization and target selection.
• AI can compress drug discovery and development timelines by 25-50%, making processes 30-50% faster than conventional methods, though scaling remains a challenge in India.

Why It Matters: AI is set to transform India's pharma and healthcare by 2026, accelerating drug discovery and operational efficiency.